UDCA联合异甘草酸镁治疗Ⅱ、Ⅲ期原发性胆汁性肝硬化患者的临床疗效观察

目的探讨熊去氧胆酸(UDCA)联合异甘草酸镁对早中期原发性胆汁性肝硬化(PBC)患者的临床疗效。方法选择我院收治的53例PBC患者,随机分为治疗组(28例)和对照组(25例),治疗组给予UDCA联合异甘草酸镁,对照组单独给予UDCA;比较两组患者临床症状改善和患者免疫指标水平变化情况。结果治疗后治疗组血清TBil、AST、ALT、γ-GGT、ALP均明显低于对照组(P0.05);治疗组治疗4周后总有效率为82.14%,对照组为60.87%,治疗组显著高于对照组,两组相比差异具有统计学意义(χ2=11.102,P=0.000)。治疗后两组患者免疫指标均显著降低,其中治疗组各免疫指标降低水平显著优于对照组,两组间相比差异具有统计学意义(P0.05)。结论 UDCA联合异甘草酸镁治疗Ⅱ、Ⅲ期PBC患者可以显著改善患者的临床症状,提高临床疗效,且不良反应轻微,可以考虑作为PBC的治疗方法之一。

The clinical effect of UDCA combined with Magnesium isoglycyrrhizinate in treatment of patients with primary biliary cirrhosis

Objective To observe the clinical effect of UDCA combined with Magnesium isoglycyrrhizinate in treatment of patients with primary biliary cirrhosis （PBC） and to analyze the immune index levels changes.Methods Fiftythree patients with PBC in our hospital were randomly divided into the treatment group and control group,the treatment group received UDCA combined with Magnesium isoglycyrrhizinate,while the control group was only given UDCA.The clinical symptoms and the changes of immunological indexes were compared between two groups.Results The levels of serum TBil,AST,ALT,γ-GGT,ALP of treatment group after treatment were significantly lower than those of the control group （P ＜0.05） ; after 4 weeks of treatment,the total effective rate was 82.14％ in treatment group,60.87％ in the control group,it was significantly higher in treatment group than that in the control group,the difference was statistically significant between two groups （x2 =11.102,P ＜ 0.05）.After treatment,the immune indexes of two group were significantly decreased.All immune indexes lower were significantly better in treatmat group than those in the control group （P ＜ 0.05）.Conclusion UDCA combined with Magnesium isoglycyrrhizinate in treatment of patients with primary biliary cirrhosis can significantly improve the clinical symptoms,improve clinical efficacy,and adverse reactions were mild,so it can be considered as one of the methods of treatment of PBC.